Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
COMBINATION_PRODUCT
2 trials
Sponsors
Fudan University
Conditions
Biliary Tract Carcinoma
Phase 1
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
NCT04979663
Fudan University
Biliary Tract Carcinoma
Start: 2020-12-01
End: 2022-06-30
Target: 10
Updated: 2021-08-09
Phase 2
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
Recruiting
NCT05668884
Fudan University
Biliary Tract Carcinoma
Start: 2022-10-18
End: 2027-03-31
Target: 93
Updated: 2026-01-14
Related Papers
Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study.
Journal of Clinical Oncology
2026-05-27